BRIDGEBIO PHARMA, INC. Environmental Analytics
Environmental and financial analysis dashboard for BRIDGEBIO PHARMA, INC.. Industry: MANUFACTURING
Company Overview for BRIDGEBIO PHARMA, INC.
Highlights
Showing data for FY2022
Operational Environmental Cost
$1.08m
Operational Environmental Cost Intensity
1.38%
Total Environmental Cost
N/A
Total Environmental Cost Intensity
N/A
ΔOperational Environmental Cost (2020-2022)
$1.01m
Decoupling Rate (2020-2022)
-28%
Adjusted EBITDA
$-399m
Adjusted EBITDA Margin
-513%
Environmental cost statement
Showing data for FY2022
| USD MM | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| OPERATIONAL SOCIAL COST OF CARBON | ||||
| 1009.32% | 33.46% | -86.91% | ||
| 0.29% | 0.38% | 0.45% | 0.49% | |
| 1076.28% | 34.31% | -84.75% | ||
| 0.56% | 0.77% | 0.93% | 1.19% | |
| $0m | $1m | $1m | $0m | |
| 1053.41% | 34.03% | -85.46% | ||
| 0.84% | 1.15% | 1.38% | 1.68% | |
| INDIRECT SOCIAL COST OF CARBON | ||||
| N/A | N/A | N/A | ||
| N/A | N/A | N/A | N/A | |
| N/A | N/A | N/A | ||
| N/A | N/A | N/A | N/A | |
All figures are denominated in millions of USD. USD is the base currency used to monetize, other currency equivalents are calculated using end of year exchange rates. Scope 2: Social Cost of Carbon is calculated using market-based emissions data. | ||||
Environmental cost bridge
Showing data for FY2022
Integrated financial analysis
Highlights
Showing data for FY2022
Adjusted EBITDA Margin
-513%
Adjusted EBIT Margin
-522%
EV / Adjusted EBITDA
Company Value: Placeholder
Industry Average: Placeholder
Coming soon
EV / Adjusted EBIT
Company Value: Placeholder
Industry Average: Placeholder
Coming soon
Integrated income statement
Showing data for FY2022
| USD MM | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| INCOME STATEMENT | ||||
$8m | $70m | $78m | $9m | |
| 745.09% | 11.37% | -88.02% | ||
$476m | $604m | $475m | $575m | |
| 5765.86% | 865.73% | 611.85% | 6178.34% | |
$-467m | $-534m | $-397m | $-565m | |
| -5665.86% | -765.73% | -511.85% | -6078.34% | |
$-469m | $-540m | $-404m | $-572m | |
| -5683.51% | -774.11% | -520.57% | -6148.15% | |
| ENVIRONMENTAL COST DATA | ||||
$0m | $1m | $1m | $0m | |
| 0.84% | 1.15% | 1.38% | 1.68% | |
| FINANCIAL DATA ADJUSTED FOR OPERATIONAL ENVIRONMENTAL COST | ||||
$-468m | $-535m | $-399m | $-565m | |
| -5666.71% | -766.88% | -513.24% | -6080.02% | |
$-469m | $-541m | $-405m | $-572m | |
| -5684.36% | -775.26% | -521.96% | -6149.83% | |
All figures are denominated in millions of USD. USD is the base currency used to monetize, other currency equivalents are calculated using end of year exchange rates. | ||||
Environmental EBITDA bridge
Showing data for FY2022
Industry benchmark
MANUFACTURE OF PHARMACEUTICAL PREPARATIONS
Scope 1 (% of Sales)
0.45%
Scope 2 (% of Sales)
0.93%
Operational Environmental Cost Intensity
1.38%
Scope 3 (% of Sales)
N/A
Total Environmental Cost Intensity
N/A
Selected peer group
Showing data for FY2022
NAME | COUNTRY | OPERATIONAL ENV. COST | OPERATIONAL ENV. COST INTENSITY |
|---|---|---|---|
BRIDGEBIO PHARMA, INC. | US | $1m | 1.38% |
Loading similar companies data...
Industry distribution
Showing data for FY2022
Note: Outliers are calculated using the 1.5 * IQR method, where values outside Q1 - 1.5 * IQR and Q3 + 1.5 * IQR are considered outliers.
Estimated Social Cost of Carbon Scope 3 breakdown
Percentage breakdown of Social Cost of Carbon Scope 3 into various categories
Showing data for FY2022
SCOPE 3 CATEGORY | Company (USD) | Company % | Industry Avg (USD) | Industry Avg % |
|---|---|---|---|---|
Purchased goods (1 & 2) | N/A | N/A | N/A | N/A |
Energy-related activities (3) | N/A | N/A | N/A | N/A |
Upstream transportation (4) | N/A | N/A | N/A | N/A |
Waste (5) | N/A | N/A | N/A | N/A |
Business travel (6) | N/A | N/A | N/A | N/A |
Commuting (7) | N/A | N/A | N/A | N/A |
Upstream leased assets (8) | N/A | N/A | N/A | N/A |
Downstream transportation (9) | N/A | N/A | N/A | N/A |
Processing of products (10) | N/A | N/A | N/A | N/A |
Use of products (11) | N/A | N/A | N/A | N/A |
Final treatment of products (12) | N/A | N/A | N/A | N/A |
Downstream leased assets (13) | N/A | N/A | N/A | N/A |
Franchises (14) | N/A | N/A | N/A | N/A |
Investments (15) | N/A | N/A | N/A | N/A |
Total | $0m | 100.00% | $0m | 100.00% |
Scope 3 breakdown visualization
Showing data for FY2022